On Monday, the Vetr crowd downgraded their rating for Johnson & Johnson JNJ from 3.5 stars (Buy), issued three days ago, to 3 stars (Hold). Crowd sentiment for the stock is mostly positive, with 66 percent of Vetr user ratings bullish.
After hitting an all-time high above $125 earlier in the year, Johnson & Johnson is still performing well despite increased competition from other pharmaceutical companies. The stock traded recently at around $15 per share.
In the wake of the recent market action from other biopharmas, Barclays downgraded Johnson & Johnson from Overweight to Equal-weight late in November.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is at $115.95, which is below the average analyst target price of $120.60. Less than 2 percent of Vetr users are holding JNJ in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.